Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.20
NYSE:ALR's Cash-to-Debt is ranked lower than
86% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. NYSE:ALR: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:ALR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.15 Max: N/A
Current: 0.2
Equity-to-Asset 0.32
NYSE:ALR's Equity-to-Asset is ranked lower than
83% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NYSE:ALR: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:ALR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.35 Max: 0.77
Current: 0.32
-0.49
0.77
Piotroski F-Score: 4
Altman Z-Score: 0.84
Beneish M-Score: -3.07
WACC vs ROIC
0.86%
-2.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -0.78
NYSE:ALR's Operating Margin % is ranked lower than
53% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. NYSE:ALR: -0.78 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:ALR' s Operating Margin % Range Over the Past 10 Years
Min: -44.13  Med: 3.88 Max: 7.6
Current: -0.78
-44.13
7.6
Net Margin % -8.04
NYSE:ALR's Net Margin % is ranked lower than
55% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. NYSE:ALR: -8.04 )
Ranked among companies with meaningful Net Margin % only.
NYSE:ALR' s Net Margin % Range Over the Past 10 Years
Min: -47.2  Med: -3.08 Max: 8.29
Current: -8.04
-47.2
8.29
ROE % -10.90
NYSE:ALR's ROE % is ranked lower than
56% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.56 vs. NYSE:ALR: -10.90 )
Ranked among companies with meaningful ROE % only.
NYSE:ALR' s ROE % Range Over the Past 10 Years
Min: -34.13  Med: -4.53 Max: 9.2
Current: -10.9
-34.13
9.2
ROA % -3.32
NYSE:ALR's ROA % is ranked higher than
50% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. NYSE:ALR: -3.32 )
Ranked among companies with meaningful ROA % only.
NYSE:ALR' s ROA % Range Over the Past 10 Years
Min: -15.33  Med: -1.1 Max: 3.23
Current: -3.32
-15.33
3.23
ROC (Joel Greenblatt) % -1.92
NYSE:ALR's ROC (Joel Greenblatt) % is ranked higher than
50% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.92 vs. NYSE:ALR: -1.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:ALR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -169.25  Med: 9.18 Max: 22.61
Current: -1.92
-169.25
22.61
3-Year Revenue Growth Rate -5.10
NYSE:ALR's 3-Year Revenue Growth Rate is ranked lower than
74% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NYSE:ALR: -5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:ALR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 8.2 Max: 73
Current: -5.1
-8.6
73
3-Year EBITDA Growth Rate -17.50
NYSE:ALR's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. NYSE:ALR: -17.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:ALR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.2  Med: 6.3 Max: 102.9
Current: -17.5
-39.2
102.9
3-Year EPS without NRI Growth Rate 23.10
NYSE:ALR's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. NYSE:ALR: 23.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:ALR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.2  Med: -9.3 Max: 76.1
Current: 23.1
-57.2
76.1
GuruFocus has detected 5 Warning Signs with Alere Inc $NYSE:ALR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:ALR's 30-Y Financials

Financials (Next Earnings Date: 2017-09-06 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALR/PB395.543.033 % Conv Perp Pfd Shs Series -B-

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:PRXL, NAS:VWR, OTCPK:SWTUY, NAS:PRAH, OTCPK:CZMWY, NYSE:CRL, NAS:BRKR, NAS:EXAS, NAS:CPHD, NAS:ICLR, NAS:NEOG, OTCPK:MRCHF, NYSE:BIO, NAS:DXCM, NAS:INCR, NAS:MYGN, NAS:AXDX, NAS:FMI, NAS:VREX, NYSE:PKI » details
Traded in other countries:IM5.Germany,
Headquarter Location:USA
Alere Inc enables individuals to take charge of improving their health and quality of life at home. The Company operates in three segments; professional diagnostics, health information solutions and consumer diagnostics.

Alere develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Top Ranked Articles about Alere Inc

Alere Inc. Announces Termination of Consent Solicitations for Alere Inc.'s Notes and Offers Consent Termination Fee
Alere Inc. Announces Commencement of Additional Consent Solicitations for Alere Inc.'s Notes
Alere Inc. Announces Successful Completion of Consent Solicitations for Alere Inc.'s Notes
Alere Inc. Announces Modifications of Consent Solicitations for Alere Inc.'s Notes
Alere Inc. Announces Commencement of Consent Solicitations for Alere Inc.'s Notes
Alere Launches the Alere™ Malaria Ag P.f, the First-Ever Rapid Test to Screen Malaria Infection in Asymptomatic Individuals
Stock Options: Covered Call Option Reports for Alere, Freeport-McMoRan, NVIDIA, Snap Inc., and Twitter include trade ideas that offer returns of 20% or more!
Abbott and Alere Amend Terms of Merger Agreement
Alere Achieves FDA Clearance for Alere™ Reader Platform and Alere BinaxNOW® Influenza A & B Card 2
First Eagle's Investments of the Last 2 Quarters Guru's 3rd- and 4th-quarter purchases
First Eagle Investment (Trades, Portfolio) is an independent firm with an estimated $97 billion in assets under management. The firm manages a portfolio composed of 334 stocks with a total value of $39.105 billion. In the third and fourth quarters of 2016 the guru bought shares in the following stocks: Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 24.63
ALR's Forward PE Ratio is ranked higher than
50% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.57 vs. ALR: 24.63 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 26.89
ALR's Price-to-Owner-Earnings is ranked higher than
59% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.56 vs. ALR: 26.89 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.13  Med: 22.39 Max: 3107.86
Current: 26.89
9.13
3107.86
PB Ratio 3.62
ALR's PB Ratio is ranked higher than
54% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. ALR: 3.62 )
Ranked among companies with meaningful PB Ratio only.
ALR' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.75 Max: 3.63
Current: 3.62
0.42
3.63
PS Ratio 1.83
ALR's PS Ratio is ranked higher than
77% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. ALR: 1.83 )
Ranked among companies with meaningful PS Ratio only.
ALR' s PS Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.43 Max: 4.22
Current: 1.83
0.52
4.22
Price-to-Free-Cash-Flow 24.32
ALR's Price-to-Free-Cash-Flow is ranked higher than
53% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. ALR: 24.32 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.03  Med: 19.93 Max: 168.64
Current: 24.32
7.03
168.64
Price-to-Operating-Cash-Flow 18.01
ALR's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.63 vs. ALR: 18.01 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.63  Med: 11.97 Max: 130
Current: 18.01
4.63
130
EV-to-EBITDA 28.39
ALR's EV-to-EBITDA is ranked lower than
67% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.45 vs. ALR: 28.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 13.9 Max: 87.3
Current: 28.39
-173.6
87.3
Current Ratio 2.08
ALR's Current Ratio is ranked lower than
58% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ALR: 2.08 )
Ranked among companies with meaningful Current Ratio only.
ALR' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.78 Max: 3.42
Current: 2.08
0.7
3.42
Quick Ratio 1.63
ALR's Quick Ratio is ranked lower than
62% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. ALR: 1.63 )
Ranked among companies with meaningful Quick Ratio only.
ALR' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.36 Max: 2.89
Current: 1.63
0.46
2.89
Days Inventory 94.88
ALR's Days Inventory is ranked lower than
55% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. ALR: 94.88 )
Ranked among companies with meaningful Days Inventory only.
ALR' s Days Inventory Range Over the Past 10 Years
Min: 80.56  Med: 93.18 Max: 104.46
Current: 94.88
80.56
104.46
Days Sales Outstanding 59.30
ALR's Days Sales Outstanding is ranked higher than
51% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.30 vs. ALR: 59.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.3  Med: 67.28 Max: 79.93
Current: 59.3
59.3
79.93
Days Payable 60.24
ALR's Days Payable is ranked higher than
52% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.24 vs. ALR: 60.24 )
Ranked among companies with meaningful Days Payable only.
ALR' s Days Payable Range Over the Past 10 Years
Min: 45.36  Med: 53.06 Max: 60.24
Current: 60.24
45.36
60.24

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.50
ALR's 5-Year Yield-on-Cost % is ranked lower than
83% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. ALR: 0.50 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.5
3-Year Average Share Buyback Ratio -2.00
ALR's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. ALR: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.8  Med: -3.4 Max: 19.3
Current: -2
-60.8
19.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.58
ALR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
72% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ALR: 1.58 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.45  Med: 1.22 Max: 6.82
Current: 1.58
0.45
6.82
Price-to-Median-PS-Value 1.29
ALR's Price-to-Median-PS-Value is ranked lower than
67% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. ALR: 1.29 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.99 Max: 2.87
Current: 1.29
0.36
2.87
Earnings Yield (Greenblatt) % -0.21
ALR's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. ALR: -0.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.4  Med: 1.2 Max: 3.1
Current: -0.21
-19.4
3.1
Forward Rate of Return (Yacktman) % -2.85
ALR's Forward Rate of Return (Yacktman) % is ranked lower than
78% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. ALR: -2.85 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.9  Med: 3 Max: 10.8
Current: -2.85
-2.9
10.8

More Statistics

Revenue (TTM) (Mil) $2,386.34
EPS (TTM) $ -2.45
Beta-0.64
Short Percentage of Float2.16%
52-Week Range $31.47 - 50.30
Shares Outstanding (Mil)87.37

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 2,439 2,501
EPS ($) 2.04 2.36
EPS without NRI ($) 2.04 2.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.80%
Dividends per Share ($) 0.25
» More Articles for ALR

Headlines

Articles On GuruFocus.com
Test Jun 28 2017 
US Market Indexes Higher on Wednesday Jun 28 2017 
Test Jun 28 2017 
British Pound Moving Higher Against US Dollar Jun 28 2017 
Bain Capital's Offer to Buy German Stada Falls Through Jun 28 2017 
Test Jun 28 2017 
Growing Competition Will Continue to Hurt Fitbit Jun 28 2017 
Rich Cigars Debuts in the OTC Pink Sheets Market Jun 28 2017 
Some More Timeless Advice From the Intelligent Investor Jun 28 2017 
Seth Klarman: Value Investing in the Tech Bubble Jun 28 2017 

More From Other Websites
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock Jun 23 2017
Featured Company News - PerkinElmer Announces Acquisition of EUROIMMUN; Set To Expand its Autoimmune... Jun 21 2017
ETFs with exposure to Alere, Inc. : June 20, 2017 Jun 20 2017
Alere, Inc. :ALR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 Jun 19 2017
Alere says feds won’t take action in billing probe Jun 15 2017
Alere reports 1Q loss Jun 14 2017
Alere Reports First Quarter 2017 Financial Results Jun 14 2017
Cramer's lightning round: This downtrodden stock's no more than a value play Jun 07 2017
Alere Inc. Announces Termination of Consent Solicitations for Alere Inc.'s Notes and Offers Consent... Jun 05 2017
Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2016 Financial Results Jun 05 2017
How Will Abbott Laboratories Benefit from Its Alere Acquisition? May 25 2017
Alere Announces Update on Form 10-K and Provides Preliminary Unaudited Financial Results May 22 2017
Are Options Traders Betting on a Big Move in Alere (ALR) Stock? May 18 2017
Greenlight Capital Quadrupled General Motors Stake in Activist Push May 16 2017
Billionaire Einhorn Trims Apple, Adds GM, Exits Yelp in Q1: 13F Filing May 16 2017
Alere Inc. Announces Successful Completion of Consent Solicitations for Alere Inc.'s Notes May 08 2017
Alere Inc. Announces Modifications of Consent Solicitations for Alere Inc.'s Notes May 04 2017
Alere, set to be acquired by Abbott, dealt setback in Medicare case May 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}